Volume 23, Number 10—October 2017
Research
Disease Burden of Clostridium difficile Infections in Adults, Hong Kong, China, 2006–2014
Table 2
Characteristics of patients with Clostridium difficile infections, Hong Kong, China, 2006–2014*
Characteristic | No. (%) patients |
||
---|---|---|---|
Overall, n = 15,753† | HA-CDI, n = 14,402 | CA-CDI, n = 817 | |
Age, y | |||
<44 | 1,040 (6.6) | 893 (6.2) | 105 (12.9) |
45–64 | 2,930 (18.6) | 2,621 (18.2) | 203 (24.8) |
65–84 | 7,026 (44.6) | 6,495 (45.1) | 301 (36.9) |
>85 | 4,757 (30.2) | 4,393 (30.5) | 208 (25.4) |
Sex | |||
M | 7,624 (48.4) | 7,028 (48.8) | 337 (41.2) |
F | 8,129 (51.6) | 7,374 (51.2) | 480 (58.8) |
Resident of home for elderly persons | 4,757 (30.2) | 4,393 (30.5) | 203 (24.9) |
Severe disease | 6,868 (43.6) | 6,294 (43.7) | 340 (41.6) |
Antimicrobial drug use‡ | |||
High-risk drug | 10,397 (66.0) | 9,822 (68.2) | 299 (36.6) |
Medium-risk drug | 11,909 (75.6) | 11,320 (78.6) | 318 (38.9) |
Low-risk drug | 221 (1.4) | 216 (1.5) | 74 (1.4) |
Diagnostic test | |||
Bacterial culture | 4,883 (31.0) | 4,421 (30.7) | 259 (31.7) |
Toxin detection | 5,246 (33.3) | 4,940 (34.3) | 195 (23.9) |
NAAT | 5,624 (35.7) | 5,041 (35.0) | 363 (44.4) |
Use of proton-pump inhibitor | 7,530 (47.8) | 7,086 (49.2) | 180 (22.0) |
Use of histamine-2 receptor antagonist | 7,451 (47.3) | 6,927 (48.1) | 273 (33.4) |
Concurrent condition | |||
Myocardial infarction | 1,497 (9.5) | 1,411 (9.8) | 29 (3.6) |
Cerebrovascular disease | 5,183 (32.9) | 4,825 (33.5) | 176 (21.6) |
Chronic lung disease | 2,410 (15.3) | 2,232 (15.5) | 100 (12.2) |
Diabetes mellitus | 2,899 (18.4) | 2,693 (18.7) | 103 (12.6) |
Renal disease | 3,592 (22.8) | 3,341 (23.2) | 113 (13.8) |
Nonmetastatic tumor | 3,970 (25.2) | 3,701 (25.7) | 134 (16.4) |
AIDS | 79 (0.5) | 58 (0.4) | 13 (1.6) |
Inflammatory bowel disease | 95 (0.6) | 58 (0.4) | 36 (4.4) |
Deaths | |||
During hospital stay | 3,733 (23.7) | 3,528 (24.5) | 51 (6.2) |
30-d all-cause | 3,544 (22.5) | 3,341 (23.2) | 80 (9.8) |
60-d all-cause | 5,088 (32.3) | 4,781 (33.2) | 106 (13.0) |
Recurrence, d§ | |||
30 | 961 (6.1) | 907 (6.3) | 17 (2.1) |
60 | 1,229 (7.8) | 1,152 (8.0) | 25 (3.0) |
90 | 1,339(8.5) | 1,267 (8.8) | 28 (3.4) |
180 | 1,481(9.4) | 1,397 (9.7) | 33 (4.0) |
*CA-CDI, community-associated C. difficile infection; CDI; HA-CDI, healthcare-associated C. difficile infection; NAAT, nucleic acid amplification test.
†Sum of HA-CDI and CA-CDI cases might not equal number of overall CDI cases because of missing information in the registry.
‡Antimicrobial drug use 8 weeks before diagnosis was stratified into high risk (floroquinolones, cephalosporins, and clindamycin); medium risk (penicillins, macrolides, and sulfonamides); and low risk (tetracyclines).
§Defined as reappearance of symptoms after initial resolution and a positive CDI test result.
1These authors contributed equally to this article.